Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.61 |
| ▸ | MEN1 | O00255 | 8/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11480404 | 0.89 | HPGD (0.59) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL7110256 | 0.89 | ALDH1A1 (0.59) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL11488577 | 0.82 | ALDH1A1 (0.59) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL5640862 | 0.81 | KMT2A (0.63) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL5658125 | 0.78 | ALDH1A1 (0.67) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL2763282 | 0.78 | KMT2A (0.68) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL5641498 | 0.77 | HPGD (0.70) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL11479637 | 0.77 | ALDH1A1 (0.65) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL7110795 | 0.77 | ALDH1A1 (0.70) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL7967809 | 0.76 | ALDH1A1 (0.48) | KMT2AMEN1ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410997-B2 | Tricyclic fused heterocycle compounds, process for preparing the same and use thereof | NIPPON SULSAN KAISHA, LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410997-B2 | Tricyclic fused heterocycle compounds, process for preparing the same and use thereof | NIPPON SULSAN KAISHA, LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20030065021-A1 | Tracheal smooth muscle relaxants | YAMASHITA SHINYA (JP) | 2003-04-03 | — | — | US | disclosed |
| US-6495592-B1 | DIBENZ(B,F)OXEPIN DERIVATIVES; ANTIASTHMATICS | NIPPON SUISAN KAISHA, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-6180659-B1 | USING A DIBENZO(B,F)-(OXEPIN OR THIEPIN) COMPOUND | NIPPON SUISAN KAISHA, LTD. (JP) | 2001-01-30 | — | — | US | disclosed |
| EP-0885610-A1 | TRACHEAL SMOOTH MUSCLE RELAXANT | NIPPON SUISAN KAISHA, LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0805155-A1 | NOVEL ANTIOXIDANT TRICYCLIC FUSED HETEROCYCLIC COMPOUND | NIPPON SUISAN KAISHA, LTD. (JP) | 1997-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065021-A1 | Tracheal smooth muscle relaxants | MYLK, MUSK, CPT1B | KMT2A 918/4885MEN1 4726/4885ALDH1A1 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.